NCT03363217View on ClinicalTrials.gov

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

August 16, 2018

Primary Completion Date

March 1, 2027

Study Completion Date

March 1, 2027

Conditions
Low-grade GliomaPlexiform NeurofibromaCentral Nervous System Glioma
Interventions
DRUG

Trametinib

Daily administration of oral trametinib at a unique dose of 0.025 mg/kg.

Trial Locations (7)

T3B 6A8

Alberta Children's Hospital, Calgary

Unknown

Children and Women's Health Centre of British Colombia, Vancouver

IWK Health Centre, Halifax

M5G 1X8

The Hospital for Sick Children, Toronto

H3T 1C5

CHU Sainte-Justine, Montreal

H4A 3J1

Montreal Children's Hospital, Montreal

G1V 4G2

CHU de Québec, Québec

All Listed Sponsors
collaborator

Montreal Children's Hospital of the MUHC

OTHER

collaborator

CHU de Quebec-Universite Laval

OTHER

lead

St. Justine's Hospital

OTHER

NCT03363217 - Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. | Biotech Hunter | Biotech Hunter